The DOI matches its Crossref record; 320 of the 320 references it cites were found in a registry or an index.
Therapeutic Targeting of the Tumor Microenvironment
Abstract
Strategies to therapeutically target the tumor microenvironment (TME) have emerged as a promising approach for cancer treatment in recent years due to the critical roles of the TME in regulating tumor progression and modulating response to standard-of-care therapies. Here, we summarize the current knowledge regarding the most advanced TME-directed therapies, which have either been clinically approved or are currently being evaluated in trials, including immunotherapies, antiangiogenic drugs, and treatments directed against cancer-associated fibroblasts and the extracellular matrix. We also discuss some of the challenges associated with TME therapies, and future perspectives in this evolving field. Significance: This review provides a comprehensive analysis of the current therapies targeting the TME, combining a discussion of the underlying basic biology with clinical evaluation of different therapeutic approaches, and highlighting the challenges and future perspectives.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
2 retracted
Items 201–320 of 320
Fearon, D. T. (2014) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-14-0002 · Cited by 288
Applying high-dimensional single-cell technologies to the analysis of cancer immunotherapy
Gohil, S. H., Iorgulescu, J. B., Braun, D. A., Keskin, D. B., & Livak, K. J. (2021) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-020-00449-x · Cited by 282
Zhou, Y., Bian, S., Zhou, X., Cui, Y., Wang, W., Wen, L., Guo, L., Fu, W., & Tang, F. (2020) · Cancer Cell · doi:10.1016/j.ccell.2020.09.015 · Cited by 278
Quail, D. F., Olson, O. C., Bhardwaj, P., Walsh, L. A., Akkari, L., Quick, M. L., Chen, I.-C., Wendel, N., Ben-Chetrit, N., Walker, J., et al. (2017) · Nature Cell Biology · doi:10.1038/ncb3578 · Cited by 277
Self-citationLaoui, D., Keirsse, J., Morias, Y., Van Overmeire, E., Geeraerts, X., Elkrim, Y., Kiss, M., Bolli, E., Lahmar, Q., Sichien, D., et al. (2016) · Nature Communications · doi:10.1038/ncomms13720 · Cited by 277
Staged induction of HIV-1 glycan–dependent broadly neutralizing antibodies
Bonsignori, M., Kreider, E. F., Fera, D., Meyerhoff, R. R., Bradley, T., Wiehe, K., Alam, S. M., Aussedat, B., Walkowicz, W. E., Hwang, K.-K., et al. (2017) · Science Translational Medicine · doi:10.1126/scitranslmed.aai7514 · Cited by 270
He, Y., Yu, H., Rozeboom, L., Rivard, C. J., Ellison, K., Dziadziuszko, R., Suda, K., Ren, S., Wu, C., Hou, L., et al. (2017) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2017.01.019 · Cited by 268
The full spectrum of human naive T cells
van den Broek, T., Borghans, J. A. M., & van Wijk, F. (2018) · Nature Reviews Immunology · doi:10.1038/s41577-018-0001-y · Cited by 264
Luo, J., Elwood, F., Britschgi, M., Villeda, S., Zhang, H., Ding, Z., Zhu, L., Alabsi, H., Getachew, R., Narasimhan, R., et al. (2013) · Journal of Experimental Medicine · doi:10.1084/jem.20120412 · Cited by 262
Tumor lymphangiogenesis promotes T cell infiltration and potentiates immunotherapy in melanoma
Fankhauser, M., Broggi, M. A. S., Potin, L., Bordry, N., Jeanbart, L., Lund, A. W., Da Costa, E., Hauert, S., Rincon-Restrepo, M., Tremblay, C., et al. (2017) · Science Translational Medicine · doi:10.1126/scitranslmed.aal4712 · Cited by 259
Rewiring T-cell responses to soluble factors with chimeric antigen receptors
Chang, Z. L., Lorenzini, M. H., Chen, X., Tran, U., Bangayan, N. J., & Chen, Y. Y. (2018) · Nature Chemical Biology · doi:10.1038/nchembio.2565 · Cited by 259
Tolaney, S. M., Boucher, Y., Duda, D. G., Martin, J. D., Seano, G., Ancukiewicz, M., Barry, W. T., Goel, S., Lahdenrata, J., Isakoff, S. J., et al. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1518808112 · Cited by 258
Edris, B., Weiskopf, K., Volkmer, A. K., Volkmer, J.-P., Willingham, S. B., Contreras-Trujillo, H., Liu, J., Majeti, R., West, R. B., Fletcher, J. A., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1121629109 · Cited by 258
Host tissue determinants of tumour immunity
Salmon, H., Remark, R., Gnjatic, S., & Merad, M. (2019) · Nature Reviews Cancer · doi:10.1038/s41568-019-0125-9 · Cited by 253
Basis of CTLA-4 function in regulatory and conventional CD4+ T cells
Tai, X., Van Laethem, F., Pobezinsky, L., Guinter, T., Sharrow, S. O., Adams, A., Granger, L., Kruhlak, M., Lindsten, T., Thompson, C. B., et al. (2012) · Blood · doi:10.1182/blood-2011-11-388918 · Cited by 251
Weber, J., Gibney, G., Kudchadkar, R., Yu, B., Cheng, P., Martinez, A. J., Kroeger, J., Richards, A., McCormick, L., Moberg, V., et al. (2016) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-15-0193 · Cited by 248
Loberg, R. D., Ying, C., Craig, M., Yan, L., Snyder, L. A., & Pienta, K. J. (2007) · Neoplasia · doi:10.1593/neo.07307 · Cited by 242
Stimulatory versus suppressive effects of GM-CSF on tumor progression in multiple cancer types
Hong, I.-S. (2016) · Experimental & Molecular Medicine · doi:10.1038/emm.2016.64 · Cited by 240
He, D., Wang, D., Lu, P., Yang, N., Xue, Z., Zhu, X., Zhang, P., & Fan, G. (2021) · Oncogene · doi:10.1038/s41388-020-01528-0 · Cited by 238
Yan, D., Kowal, J., Akkari, L., Schuhmacher, A. J., Huse, J. T., West, B. L., & Joyce, J. A. (2017) · Oncogene · doi:10.1038/onc.2017.261 · Cited by 236
Self-citationLiu, Q., Yang, C., Wang, S., Shi, D., Wei, C., Song, J., Lin, X., Dou, R., Bai, J., Xiang, Z., et al. (2020) · Cell Communication and Signaling · doi:10.1186/s12964-020-00557-2 · Cited by 226
Zhao, L., Lim, S. Y., Gordon-Weeks, A. N., Tapmeier, T. T., Im, J. H., Cao, Y., Beech, J., Allen, D., Smart, S., & Muschel, R. J. (2013) · Hepatology · doi:10.1002/hep.26094 · Cited by 225
Phase I Study of Recombinant Human CD40 Ligand in Cancer Patients
Vonderheide, R. H., Dutcher, J. P., Anderson, J. E., Eckhardt, S. G., Stephans, K. F., Razvillas, B., Garl, S., Butine, M. D., Perry, V. P., Armitage, R. J., et al. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.13.3280 · Cited by 223
Adjustment of dendritic cells to the breast-cancer microenvironment is subset specific
Michea, P., Noël, F., Zakine, E., Czerwinska, U., Sirven, P., Abouzid, O., Goudot, C., Scholer-Dahirel, A., Vincent-Salomon, A., Reyal, F., et al. (2018) · Nature Immunology · doi:10.1038/s41590-018-0145-8 · Cited by 223
Cavalcanti, M. G., Cunha, A. F. A., & Peralta, J. M. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00858 · Cited by 223
Nano-Enhanced Drug Delivery and Therapeutic Ultrasound for Cancer Treatment and Beyond
Tharkar, P., Varanasi, R., Wong, W. S. F., Jin, C. T., & Chrzanowski, W. (2019) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2019.00324 · Cited by 223
Using paleo-archives to safeguard biodiversity under climate change
Fordham, D. A., Jackson, S. T., Brown, S. C., Huntley, B., Brook, B. W., Dahl-Jensen, D., Gilbert, M. T. P., Otto-Bliesner, B. L., Svensson, A., Theodoridis, S., et al. (2020) · Science · doi:10.1126/science.abc5654 · Cited by 221
Rapid activation of tumor-associated macrophages boosts preexisting tumor immunity
Hoves, S., Ooi, C.-H., Wolter, C., Sade, H., Bissinger, S., Schmittnaegel, M., Ast, O., Giusti, A. M., Wartha, K., Runza, V., et al. (2018) · Journal of Experimental Medicine · doi:10.1084/jem.20171440 · Cited by 219
An Expression Signature Classifies Chemotherapy-Resistant Pediatric Osteosarcoma
Mintz, M. B., Sowers, R., Brown, K. M., Hilmer, S. C., Mazza, B., Huvos, A. G., Meyers, P. A., LaFleur, B., McDonough, W. S., Henry, M. M., et al. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-2463 · Cited by 215
Morales, J. K., Kmieciak, M., Knutson, K. L., Bear, H. D., & Manjili, M. H. (2010) · Breast Cancer Research and Treatment · doi:10.1007/s10549-009-0622-8 · Cited by 214
The conservation value of human-modified landscapes for the world’s primates
Galán-Acedo, C., Arroyo-Rodríguez, V., Andresen, E., Verde Arregoitia, L., Vega, E., Peres, C. A., & Ewers, R. M. (2019) · Nature Communications · doi:10.1038/s41467-018-08139-0 · Cited by 213
Anandasabapathy, N., Victora, G. D., Meredith, M., Feder, R., Dong, B., Kluger, C., Yao, K., Dustin, M. L., Nussenzweig, M. C., Steinman, R. M., et al. (2011) · Journal of Experimental Medicine · doi:10.1084/jem.20102657 · Cited by 207
Pancreatic Stellate Cells Radioprotect Pancreatic Cancer Cells through β1-Integrin Signaling
Mantoni, T. S., Lunardi, S., Al-Assar, O., Masamune, A., & Brunner, T. B. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-1633 · Cited by 206
Blazar, B. R., Lindberg, F. P., Ingulli, E., Panoskaltsis-Mortari, A., Oldenborg, P.-A., Iizuka, K., Yokoyama, W. M., & Taylor, P. A. (2001) · The Journal of Experimental Medicine · doi:10.1084/jem.194.4.541 · Cited by 206
Amin, A., Dudek, A. Z., Logan, T. F., Lance, R. S., Holzbeierlein, J. M., Knox, J. J., Master, V. A., Pal, S. K., Miller, W. H., Karsh, L. I., et al. (2015) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-015-0055-3 · Cited by 205
CD226 opposes TIGIT to disrupt Tregs in melanoma
Fourcade, J., Sun, Z., Chauvin, J.-M., Ka, M., Davar, D., Pagliano, O., Wang, H., Saada, S., Menna, C., Amin, R., et al. (2018) · JCI Insight · doi:10.1172/jci.insight.121157 · Cited by 199
Yang, Y., Zou, J.-P., Mu, J., Wijesuriya, R., Ono, S., Walunas, T. L., Bluestone, J. A., Fujiwara, H., & Hamaoka, T. (1997) · PubMed · Cited by 197
Benson, A. B., Wainberg, Z. A., Hecht, J. R., Vyushkov, D., Dong, H., Bendell, J., & Kudrik, F. (2017) · The Oncologist · doi:10.1634/theoncologist.2017-0024 · Cited by 195
Pericellular proteolysis in cancer
Sevenich, L., & Joyce, J. A. (2014) · Genes & Development · doi:10.1101/gad.250647.114 · Cited by 193
Self-citationGenoud, V., Marinari, E., Nikolaev, S. I., Castle, J. C., Bukur, V., Dietrich, P.-Y., Okada, H., & Walker, P. R. (2018) · OncoImmunology · doi:10.1080/2162402x.2018.1501137 · Cited by 193
Truxova, I., Kasikova, L., Hensler, M., Skapa, P., Laco, J., Pecen, L., Belicova, L., Praznovec, I., Halaska, M. J., Brtnicky, T., et al. (2018) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-018-0446-3 · Cited by 191
Radiation Therapy Induces Macrophages to Suppress T-Cell Responses Against Pancreatic Tumors in Mice
Seifert, L., Werba, G., Tiwari, S., Giao Ly, N. N., Nguy, S., Alothman, S., Alqunaibit, D., Avanzi, A., Daley, D., Barilla, R., et al. (2016) · Gastroenterology · doi:10.1053/j.gastro.2016.02.070 · Cited by 190
Personalized Dendritic Cell Vaccines‐Recent Breakthroughs and Encouraging Clinical Results
Mastelic-Gavillet, B., Balint, K., Boudousquie, C., Gannon, P. O., & Kandalaft, L. E. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00766 · Cited by 189
Burugu, S., Gao, D., Leung, S., Chia, S. K., & Nielsen, T. O. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx557 · Cited by 189
Chemotherapy induces dynamic immune responses in breast cancers that impact treatment outcome
Park, Y. H., Lal, S., Lee, J. E., Choi, Y.-L., Wen, J., Ram, S., Ding, Y., Lee, S.-H., Powell, E., Lee, S. K., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-19933-0 · Cited by 186
Daud, A. I., Mirza, N., Lenox, B., Andrews, S., Urbas, P., Gao, G. X., Lee, J.-H., Sondak, V. K., Riker, A. I., DeConti, R. C., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.13.9048 · Cited by 184
Baghdadi, M., Wada, H., Nakanishi, S., Abe, H., Han, N., Putra, W. E., Endo, D., Watari, H., Sakuragi, N., Hida, Y., et al. (2016) · Cancer Research · doi:10.1158/0008-5472.can-16-1170 · Cited by 180
Evolving Roles for Targeting CTLA-4 in Cancer Immunotherapy
Zhao, Y., Yang, W., Huang, Y., Cui, R., Li, X., & Li, B. (2018) · Cellular Physiology and Biochemistry · doi:10.1159/000490025 · Cited by 179
The clinical application of cancer immunotherapy based on naturally circulating dendritic cells
Bol, K. F., Schreibelt, G., Rabold, K., Wculek, S. K., Schwarze, J. K., Dzionek, A., Teijeira, A., Kandalaft, L. E., Romero, P., Coukos, G., et al. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0580-6 · Cited by 179
Benner, B., Good, L., Quiroga, D., Schultz, T. E., Kassem, M., Carson, W. E., Cherian, M. A., Sardesai, S., & Wesolowski, R. (2020) · Drug Design, Development and Therapy · doi:10.2147/dddt.s253232 · Cited by 177
Frohne, C. C., Llano, E. M., Perkovic, A., Cohen, R. D., & Luke, J. J. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-018-0484-x · Cited by 171
Wesolowski, R., Sharma, N., Reebel, L., Rodal, M. B., Alexandra, P., West, B. L., Marimuthu, A., Severson, P. L., Karlin, D. A., Dowlati, A., et al. (2019) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758835919854238 · Cited by 169
Dendritic cells in the tumor microenvironment: prognostic and theranostic impact
Verneau, J., Sautés-Fridman, C., & Sun, C.-M. (2020) · Seminars in Immunology · doi:10.1016/j.smim.2020.101410 · Cited by 165
Apoptosis of tumor infiltrating effector TIM-3+CD8+ T cells in colon cancer
Kang, C.-W., Dutta, A., Chang, L.-Y., Mahalingam, J., Lin, Y.-C., Chiang, J.-M., Hsu, C.-Y., Huang, C.-T., Su, W.-T., Chu, Y.-Y., et al. (2015) · Scientific Reports · doi:10.1038/srep15659 · Cited by 163
Re-Education of Macrophages as a Therapeutic Strategy in Cancer
Kowal, J., Kornete, M., & Joyce, J. A. (2019) · Immunotherapy · doi:10.2217/imt-2018-0156 · Cited by 161
Self-citationDoherty, G. J., Tempero, M. A., & Corrie, P. G. (2017) · Future Oncology · doi:10.2217/fon-2017-0338 · Cited by 158
Bhome, R., Goh, R. W., Bullock, M. D., Pillar, N., Thirdborough, S. M., Mellone, M., Mirnezami, R., Galea, D., Veselkov, K., Gu, Q., et al. (2017) · Aging · doi:10.18632/aging.101355 · Cited by 155
Rüter, J., Antonia, S. J., Burris, H. A., Huhn, R. D., & Vonderheide, R. H. (2010) · Cancer Biology & Therapy · doi:10.4161/cbt.10.10.13251 · Cited by 155
Alicea, G. M., Rebecca, V. W., Goldman, A. R., Fane, M. E., Douglass, S. M., Behera, R., Webster, M. R., Kugel, C. H., Ecker, B. L., Caino, M. C., et al. (2020) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-0329 · Cited by 151
Tumor-Associated Macrophages Suppress the Cytotoxic Activity of Antimitotic Agents
Olson, O. C., Kim, H.-J., Quail, D. F., Foley, E. A., & Joyce, J. A. (2017) · Cell Reports · doi:10.1016/j.celrep.2017.03.038 · Cited by 150
Self-citationMehrotra, S., Britten, C. D., Chin, S. H., Garrett-Mayer, E. S., Cloud, C. A., Li, M., Scurti, G. M., Salem, M. L., Nelson, M. H., Thomas, M. B., et al. (2017) · Journal of Hematology & Oncology · doi:10.1186/s13045-017-0459-2 · Cited by 146
FAK activity sustains intrinsic and acquired ovarian cancer resistance to platinum chemotherapy
Diaz Osterman, C. J., Ozmadenci, D., Kleinschmidt, E. G., Taylor, K. N., Barrie, A. M., Jiang, S., Bean, L. M., Sulzmaier, F. J., Jean, C., Tancioni, I., et al. (2019) · eLife · doi:10.7554/elife.47327 · Cited by 145
Takeuchi, S., Baghdadi, M., Tsuchikawa, T., Wada, H., Nakamura, T., Abe, H., Nakanishi, S., Usui, Y., Higuchi, K., Takahashi, M., et al. (2015) · Cancer Research · doi:10.1158/0008-5472.can-14-2921 · Cited by 145
Ma, W., Wang, Y., Zhang, R., Yang, F., Zhang, D., Huang, M., Zhang, L., Dorsey, J. F., Binder, Z. A., O’Rourke, D. M., et al. (2020) · Nature Cancer · doi:10.1038/s43018-020-00147-8 · Cited by 143 · cited 2×
“One recent example involved inhibition of the PAK4 enzyme (which is selectively expressed in glioblastoma blood vessels) in combination with delivery of CAR T cells engineered to target the EGFRvIII mutation in glioma cells (290).”
The soluble isoform of CTLA‐4 as a regulator of T‐cell responses
Ward, F. J., Dahal, L. N., Wijesekera, S. K., Abdul-Jawad, S., Kaewarpai, T., Xu, H., Vickers, M. A., & Barker, R. N. (2013) · European Journal of Immunology · doi:10.1002/eji.201242529 · Cited by 142
Differential Effects of IL-12 on Tregs and Non-Treg T Cells: Roles of IFN-γ, IL-2 and IL-2R
Zhao, J., Zhao, J., & Perlman, S. M. (2012) · PLoS ONE · doi:10.1371/journal.pone.0046241 · Cited by 142
Fennell, D. A., Baas, P., Taylor, P., Nowak, A. K., Gilligan, D., Nakano, T., Pachter, J. A., Weaver, D. T., Scherpereel, A., Pavlakis, N., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.2018.79.0543 · Cited by 142
Hecht, J. R., Benson, A. B., Михайлович, В. Д., Yang, Y., Bendell, J. C., & Verma, U. N. (2017) · The Oncologist · doi:10.1634/theoncologist.2016-0479 · Cited by 141
Tumor-Associated Lymphatic Vessel Features and Immunomodulatory Functions
Garnier, L., Gkountidi, A., & Hugues, S. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00720 · Cited by 141
Monocyte Chemoattractant Protein-1 Serum Levels in Patients with Breast Cancer
Lebrecht, A., Grimm, C., Lantzsch, T., Ludwig, E., Hefler, L., Ulbrich, E. J., & Koelbl, H. (2004) · Tumor Biology · doi:10.1159/000077718 · Cited by 131
Local and Systemic Protumorigenic Effects of Cancer-Associated Fibroblast-Derived GDF15
Bruzzese, F., Hägglöf, C., Leone, A., Sjöberg, E., Roca, M. S., Kiflemariam, S., Sjöblom, T., Hammarsten, P., Egevad, L., Bergh, A., et al. (2014) · Cancer Research · doi:10.1158/0008-5472.can-13-2259 · Cited by 127
Towards extracellular matrix normalization for improved treatment of solid tumors
Abyaneh, H. S., Regenold, M., McKee, T. D., Allen, C. J., & Gauthier, M. A. (2020) · Theranostics · doi:10.7150/thno.39995 · Cited by 127
Goveia, J., Rohlenova, K., Taverna, F., Treps, L., Conradi, L.-C., Pircher, A., Geldhof, V., de Rooij, L. P. M. H., Kalucka, J., Sokol, L., et al. (2020) · Cancer Cell · doi:10.1016/j.ccell.2020.03.002 · Cited by 125
Fang, W. B., Yao, M., Brummer, G., Acevedo, D., Alhakamy, N. A., Berkland, C. J., & Cheng, N. (2016) · Oncotarget · doi:10.18632/oncotarget.9885 · Cited by 124
The Future of Immune Checkpoint Cancer Therapy After PD-1 and CTLA-4
Hahn, A. W., Gill, D. M., Pal, S. K., & Agarwal, N. (2017) · Immunotherapy · doi:10.2217/imt-2017-0024 · Cited by 123
Bell, R., Brown, J. M., Parmar, M., Toi, M., Suter, T. M., Steger, G. G., Pivot, X. B., Mackey, J. R., Jackisch, C., Dent, R. A., et al. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw665 · Cited by 118
Chang, Q., Ornatsky, O., Siddiqui, I. F. S., Straus, R., Baranov, V. I., & Hedley, D. W. (2016) · Scientific Reports · doi:10.1038/srep36641 · Cited by 116
Ansems, M., & Span, P. N. (2020) · Clinical and Translational Radiation Oncology · doi:10.1016/j.ctro.2020.04.001 · Cited by 116
Kraman, M., Faroudi, M., Allen, N. L., Kmiecik, K., Gliddon, D., Seal, C. J., Koers, A., Wydro, M. M., Batey, S., Winnewisser, J., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-3548 · Cited by 113
Anandasabapathy, N., Breton, G., Hurley, A., Caskey, M. F., Trumpfheller, C., Sarma, P., Pring, J., Pack, M., Buckley, N., Matei, I. R., et al. (2015) · Bone Marrow Transplantation · doi:10.1038/bmt.2015.74 · Cited by 105
Zhang, Y., Cai, P., Liang, T., Wang, L., & Hu, L. (2017) · Oncotarget · doi:10.18632/oncotarget.15954 · Cited by 105
Zhang, B., Wu, Q., Zhou, Y. L., Guo, X., Ge, J., & Fu, J. (2018) · International Immunopharmacology · doi:10.1016/j.intimp.2018.08.014 · Cited by 104
Hidalgo, M. M., Martinez‐García, M., Tourneau, C. L., Massard, C., Garralda, E., Boni, V., Taus, Á., Albanell, J., Sablin, M., Alt, M., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-1588 · Cited by 102
Wang, L., Nanayakkara, G., Yang, Q., Tan, H., Drummer, C., Sun, Y., Shao, Y., Fu, H., Cueto, R., Shan, H., et al. (2017) · Journal of Hematology & Oncology · doi:10.1186/s13045-017-0526-8 · Cited by 101
Vergote, I. B., Scambia, G., O’Malley, D. M., CALSTER, B. V., Park, S., del Campo, J. M., Meier, W., Bamias, A., Colombo, N., Wenham, R. M., et al. (2019) · The Lancet Oncology · doi:10.1016/s1470-2045(19)30178-0 · Cited by 95
LKB1 loss promotes endometrial cancer progression via CCL2-dependent macrophage recruitment
Peña, C. G., Nakada, Y., Saatcioglu, H. D., Aloisio, G. M., Cuevas, I., Zhang, S., Miller, D. S., Lea, J. S., Wong, K., DeBerardinis, R. J., et al. (2015) · Journal of Clinical Investigation · doi:10.1172/jci82152 · Cited by 94
Beckermann, K. E., Jolly, P. C., Kim, J. Y., Bordeaux, J., Puzanov, I. J., Rathmell, W. K., & Johnson, D. B. (2017) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-016-0206-1 · Cited by 87
He, B., Johansson, A., Backhouse, J., Li, J., Lee, G., Hamzah, J., & Ganß, R. (2020) · Cell Reports · doi:10.1016/j.celrep.2019.12.013 · Cited by 85
Boeckelmann, L., & Schumacher, U. (2019) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2019.1702974 · Cited by 84
Can we harness the microbiota to enhance the efficacy of cancer immunotherapy?
Finlay, B. B., Goldszmid, R., Honda, K., Trinchieri, G., Wargo, J., & Zitvogel, L. (2020) · Nature Reviews Immunology · doi:10.1038/s41577-020-0374-6 · Cited by 81 · cited 1×
“These pioneering findings underline the potential of microbiome-targeting therapies that will be evaluated in numerous clinical trials in the coming years (201).”
Dufait, I., Schwarze, J. K., Liechtenstein, T., Leonard, W., Jiang, H., Escors, D., Ridder, M. D., & Breckpot, K. (2015) · Oncotarget · doi:10.18632/oncotarget.3682 · Cited by 81
Semaphorins in Angiogenesis and Autoimmune Diseases: Therapeutic Targets?
Iragavarapu‐Charyulu, V., Wojcikiewicz, E. P., & Urdaneta, A. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00346 · Cited by 76
CD44 enhances tumor aggressiveness by promoting tumor cell plasticity
Paulis, Y. W. J., Huijbers, E. J. M., van der Schaft, D. W. J., Soetekouw, P. M. M. B., Pauwels, P., Tjan‐Heijnen, V. C. G., & Griffioen, A. W. (2015) · Oncotarget · doi:10.18632/oncotarget.3839 · Cited by 73
Enhancing Dendritic Cell Therapy in Solid Tumors with Immunomodulating Conventional Treatment
Belderbos, R. A., Aerts, J. G. J. V., & Vroman, H. H. (2019) · Molecular Therapy — Oncolytics · doi:10.1016/j.omto.2019.03.007 · Cited by 73
Concepts for agonistic targeting of CD40 in immuno-oncology
Richards, D. M., Sefrin, J. P., Gieffers, C., Hill, O., & Merz, C. (2019) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2019.1653744 · Cited by 73
Scholl, S., Lidereau, R., de la Rochefordière, A., Le-Nir, C. C.-S., Mosseri, V., Noguès, C., Pouillart, P., & Stanley, E. R. (1996) · Breast Cancer Research and Treatment · doi:10.1007/bf01806155 · Cited by 70
Dendritic Cell-Based Vaccine Efficacy: Aiming for Hot Spots
Pizzurro, G. A., & Barrio, M. M. (2015) · Frontiers in Immunology · doi:10.3389/fimmu.2015.00091 · Cited by 69
Intraepithelial T cells and tumor-associated macrophages in ovarian cancer patients.
Mhawech-Fauceglia, P. Y., Wang, D., Ali, L., Lele, S., Huba, M. A., Liu, S., & Odunsi, K. O. (2013) · Europe PMC (PubMed Central) · Cited by 67
Laurell, A., Lönnemark, M., Brekkan, E., Magnusson, A., Tolf, A., Wallgren, A. C., Andersson, B. A., Adamson, L., Kiessling, R. W., & Karlsson‐Parra, A. (2017) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-017-0255-0 · Cited by 64
Bordry, N., Broggi, M. A. S., de Jonge, K., Schaeuble, K., Gannon, P. O., Foukas, P. G., Danenberg, E., Romano, E., Baumgaertner, P., Fankhauser, M., et al. (2018) · OncoImmunology · doi:10.1080/2162402x.2018.1462878 · Cited by 64
Qian, C., Tan, M., Yang, J., & Cao, Y. (2016) · 癌症:英文版 · doi:10.1186/s40880-015-0070-2 · Cited by 63
Vanneste, M., Feddersen, C. R., Varzavand, A., Zhu, E. Y., Foley, T. M., Zhao, L. Q., Holt, K. H., Milhem, M. M., Piper, R. C., Stipp, C. S., et al. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.00442 · Cited by 60
Riaz, M., Sieuwerts, A. M., Look, M. P., Timmermans, M. A. M., Smid, M., Foekens, J. A., & Martens, J. W. M. (2012) · Breast Cancer Research · doi:10.1186/bcr3317 · Cited by 59
Antiangiogenic immunotherapy suppresses desmoplastic and chemoresistant intestinal tumors in mice
Ragusa, S., Prat-Luri, B., González-Loyola, A., Nassiri, S., Squadrito, M. L., Guichard, A., Cavin, S., Gjorevski, N., Barras, D., Marra, G., et al. (2020) · Journal of Clinical Investigation · doi:10.1172/jci129558 · Cited by 56 · cited 2×
“Another intriguing study in mouse colorectal cancer models showed that adaptive resistance to chemotherapy (5-FU and cisplatin) is associated with a pronounced stromal response and T-cell exclusion (291).”
The expanding landscape of inflammatory cells affecting cancer therapy
Weissleder, R., & Pittet, M. J. (2020) · Nature Biomedical Engineering · doi:10.1038/s41551-020-0524-y · Cited by 55
All systems go: converging synthetic biology and combinatorial treatment for CAR-T cell therapy
Lanitis, E., Coukos, G., & Irving, M. B. (2020) · Current Opinion in Biotechnology · doi:10.1016/j.copbio.2020.01.009 · Cited by 52
Hypoxia: Turning vessels into vassals of cancer immunotolerance
Schito, L., & Rey, S. (2020) · Cancer Letters · doi:10.1016/j.canlet.2020.05.015 · Cited by 49
Angiopoietin-1 and Angiopoietin-2 Inhibitors: Clinical Development
Gillen, J. M., Richardson, D. L., & Moore, K. N. (2019) · Current Oncology Reports · doi:10.1007/s11912-019-0771-9 · Cited by 48
A Window of Opportunity: Targeting Cancer Endothelium to Enhance Immunotherapy
Duru, G., van Egmond, M., & Heemskerk, N. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.584723 · Cited by 48
Ionizing radiation induces tumor cell lysyl oxidase secretion
Shen, C. J., Sharma, A., Vuong, D.-V., Erler, J. T., Pruschy, M. N., & Broggini‐Tenzer, A. (2014) · BMC Cancer · doi:10.1186/1471-2407-14-532 · Cited by 42
Boere, I. A., Hamberg, P., & Sleijfer, S. (2009) · Cancer Science · doi:10.1111/j.1349-7006.2009.01369.x · Cited by 38
Hernandez, M. G. H., Shen, L., & Rock, K. L. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.180.7.4382 · Cited by 35
Hingorani, S. R., Bullock, A. J., Seery, T. E., Zheng, L., Sigal, D. S., Ritch, P. S., Braiteh, F. S., Zalupski, M. M., Bahary, N., Harris, W. P., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.35.15_suppl.4008 · Cited by 35
Discovery of TSR-022, a novel, potent anti-human TIM-3 therapeutic antibody
Murtaza, A., Laken, H., Correia, J. D. S., McNeeley, P. A., Altobell, L. J., Zhang, J., Vancutsem, P. M., Wilcoxen, K., & Jenkins, D. (2016) · European Journal of Cancer · doi:10.1016/s0959-8049(16)32903-3 · Cited by 34
Shen, J., Wang, L., Zou, Z., Kong, W.-W., Yan, J., Meng, F., Chen, F., Du, J., Shao, J., Xu, Q.-P., et al. (2017) · World Journal of Gastroenterology · doi:10.3748/wjg.v23.i29.5395 · Cited by 31
Targeting Stroma: A Tale of Caution
Wang-Gillam, A. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.19.00056 · Cited by 30 · cited 1×
“This is reflected in the toxicities and secondary adverse effects that have been reported in some of the clinical trials (274).”
Beyond PD-1 Immunotherapy in Malignant Melanoma
Kwiatkowska, D., Kluska, P., & Reich, A. (2019) · Dermatology and Therapy · doi:10.1007/s13555-019-0292-3 · Cited by 25
Radiotherapy and Immunotherapy Combinations for Lung Cancer
Agrawal, V., Benjamin, K. T., & Ko, E. C. (2020) · Current Oncology Reports · doi:10.1007/s11912-020-00993-w · Cited by 23
Xu, R., Xu, C., Liu, C., Cui, C., & Zhu, J. (2018) · OncoTargets and Therapy · doi:10.2147/ott.s171724 · Cited by 21
Synovial colony-stimulating factor-1 mRNA expression in diffuse pigmented villonodular synovitis.
Molena, B., Sfriso, P., Oliviero, F., Pagnin, E., Teramo, A., Lunardi, F., Stramare, R., Scanu, A., Nardacchione, R., Rubaltelli, L., et al. (2011) · PubMed · Cited by 20
Cited by
The evolving tumor microenvironment: From cancer initiation to metastatic outgrowth
de Visser, K. E., & Joyce, J. A. (2023) · Cancer Cell · doi:10.1016/j.ccell.2023.02.016 · Cited by 4,059
Self-citationAnand, U., Dey, A., Chandel, A. K. S., Sanyal, R., Mishra, A., Pandey, D. K., De Falco, V., Upadhyay, A., Kandimalla, R., Chaudhary, A., et al. (2023) · Genes & Diseases · doi:10.1016/j.gendis.2022.02.007 · Cited by 1,834
Notch signaling pathway: architecture, disease, and therapeutics
Zhou, B., Lin, W., Long, Y., Yang, Y., Zhang, H., Wu, K., & Chu, Q. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-00934-y · Cited by 1,114
Gerstberger, S., Jiang, Q., & Ganesh, K. (2023) · Cell · doi:10.1016/j.cell.2023.03.003 · Cited by 913
Clinical relevance of tumour-associated macrophages
Pittet, M. J., Michielin, O., & Migliorini, D. (2022) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-022-00620-6 · Cited by 731
Metadata
- Authors
- Bejarano, L., Jordāo, M. J. C., & Joyce, J. A.
- Venue
- Cancer Discovery
- Published
- 2021-04-01
- Volume
- 11
- Issue
- 4
- Pages
- 933-959
- ISSN
- 2159-8274 (ISSN-L)
- 2159-8290
- OpenAlex
- W3144992645
- Cited by
- 1,653
- References
- 320
- FWCI
- 84.06
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.